Quarterly Updates16 Feb 2026, 11:29 am
Sanjivani Paranteral Ltd Reports 20.25% YoY Revenue Growth in Q3 FY26
AI Summary
Sanjivani Paranteral Ltd, a Mumbai-based pharmaceutical company, reported a strong performance in Q3 FY26 with a 20.25% YoY increase in revenue from operations. The company's acquisition of SPL Infusion Pvt. Ltd., Pune, has contributed to consolidated revenues for the first time, strengthening its manufacturing footprint and supporting overall topline growth. The core business continues to show resilience and positive momentum across key markets. The Pune facility is expected to drive steady growth with improved capacity utilization.
Key Highlights
- Revenue from operations grew by 20.25% YoY to Rs. 208.63 mn in Q3 FY26.
- SPL Infusion Pvt. Ltd., Pune, contributed to consolidated revenues for the first time.
- The Pune facility has strengthened the company's manufacturing footprint and supported overall topline growth.
- Core business demonstrates resilience and positive momentum across key markets.
- Expanded manufacturing capabilities, widening geographic reach, and strengthening product pipeline are expected to drive steady growth.